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ABSTRACT
SETTING: Breast tuberculosis (TB) is rare in Western Europe and its diagnosis may be delayed through lack of awareness of presenting features. Our institution serves a large East London population with a high prevalence of TB; annual rate 26.4-58.2 per 100,0001. 
OBJECTIVE: To characterize presenting features of breast TB and avoidable diagnostic delay. 
DESIGN: We conducted a 13-year retrospective study of breast TB patients treated at our institution including demographic, clinical, microbiology and pathology data. 
RESULTS: Forty-seven cases were included; 44 (94%) were female, with a median age of 33 years (IQR 28.5-39.5). The main presenting feature was a breast lump in 41 cases (87%); which were predominantly solitary unilateral lesions (25, 61%) and frequently located in the upper outer quadrant (28, 68%). Mycobacterium tuberculosis was cultured in 15 cases (32%). Granulomata were present on biopsy or aspirate in 21 (47%) and 17 (36%) cases respectively. The median duration between symptom onset and treatment was 137 days (IQR 107-217.5). Forty-six (98%) completed treatment successfully and one relapsed. 








Breast tuberculosis (TB) is rare but increasingly reported in Western Europe, accounting for 4.5% of all breast lesions in TB-endemic areas and 0.1% in the developed world2-4. The presenting features may mimic other breast pathology including bacterial abscess, idiopathic granulomatous mastitis or a carcinoma making diagnosis challenging. Risk factors for the development of breast TB include immunosuppression, lactation, multiparity and previous exposure to TB6. 

The majority of previous breast TB series are reported from countries of high TB incidence and there is limited evidence to aid clinical decision making in a low TB incidence country such as the UK2-8. There are no national UK guidelines for the investigation and management of breast TB.  The National Institute for Clinical Excellence (NICE) advises investigation of all breast lumps in a breast clinic, therefore breast TB patients are often referred to breast clinic on suspicion of cancer9. Initial investigations may not include mycobacterial culture and patients may undergo several diagnostic procedures before TB is considered. Consequently, referral to a TB service and initiation of appropriate therapy is often delayed3-5.  

The study was based at a large tertiary centre which serves a population of 2.6 million in East London10. The average annual rates of TB in our region are among the highest nationally; ranging from 26.4 to 58.2 per 100,0001.  We present an observational study of 47 patients treated for breast TB, characterising clinical presenting features and diagnostic delays. 

MATERIALS AND METHODS
We performed a retrospective study of consecutive patients of breast TB treated at our institution between September 2005 and May 2018. Patients were identified via the London TB register (LTBR). Cases were excluded if there were no clinical, radiological and microbiological data available. Data were collected on demographics, clinical, radiological, microbiological and histopathological findings. Furthermore, data on symptom onset, date of first review by a healthcare-professional, and date of treatment initiation were collated. It was not necessary to seek ethical approval or informed consent as this study falls under the remit of audit.

RESULTS
Over the 13-year study period, 53 cases were treated for breast TB at our institution. After exclusion of 6 cases due to insufficient data, 47 were included in our analysis. Patients were predominantly female (44, 94%), and of South Asian ethnicity (30, 64%) (table 1). For those born outside the UK the median time from entry to the UK to presentation was nine years (IQR 5-18.75). The most common presenting features were breast lump (41, 87%) in the upper outer quadrant (28/32, 88%) and breast pain (24, 51%), with few exhibiting constitutional symptoms (2, 4%) (table 2). Patients were most commonly referred to TB services from breast clinic (33, 70%) or other secondary care services (12, 26%). 

Erythrocyte sedimentation rate (ESR) was raised in 25 (53%) cases (median 29mm/hr, IQR 17.5-45.5). C-reactive protein (CRP) was mildly elevated in 14 (30%) cases (median 7 mg/L, IQR 5-21). Radiological, microbiological and histological findings are summarised in table 3. Mycobacterial culture was positive in 15/36 (42%) and non-necrotising granulomata identified on histological and cytological examination on 12/36 (33%) and 13/23 (57%) respectively (table 2 and figure 2).  The diagnostic yield of mycobacterial culture of affected breast tissue was 29% and 25% in lymph node specimens (p=0.81). Twenty (43%) cases underwent two or more fine-needle aspirations and 12 (26%) underwent two or more core biopsies before diagnosis.  Four (8.5%) underwent surgical incision and drainage (I&D) of breast abscess with one undergoing four I&D procedures prior to diagnosis. The median length of time between symptom onset and treatment initiation was 137 days (IQR 107-217.5 days) (figure 1). 

All patients received anti-tubercular therapy (ATT), however in 4 (9%) the regimen was not specified. Where ATT regimen was specified 38/43 (88%) received standard quadruple therapy (2 months of rifampicin (R), isoniazid (H), pyrazinamide (Z) and ethambutol (E) followed by 4 months of RH). The remaining 5/43 (12%) received triple therapy; 3 received 12 months of RZE due to isoniazid mono-resistance, 1 received RHZ as fully sensitive TB was confirmed prior to treatment, and in 1 case RZE was chosen to avoid interactions with chemotherapy. Patients were treated for 6-12 months (median 6, IQR 6-7 months). In 7 cases (16%) treatment was extended to 7-12 months.

Forty-six (98%) cases were successfully treated. There was 1 recurrence; she initially completed six months of empiric TB therapy during which breast symptoms and night sweats had improved, however these recurred three months later.  Repeat cultures were again negative and 10 further months of TB therapy resulted in lasting clinical cure. In 6 (13%) cases there were residual breast symptoms following resolution of infection, consisting of persistent breast pain or lumps. None required reconstructive surgery.

CONCLUSION
Diagnosis of breast TB is difficult; often necessitating multiple clinic consultations and tissue sampling procedures resulting in delays in initiating TB treatment.  Most patients in our study had been symptomatic for more than four months before TB treatment was initiated; nearly double the national median delay for treatment initiation for pulmonary TB (79 days) but similar to other breast TB series where delays of up to two years have been reported1,4,5,7. 

Nationally TB incidence is 13 times higher in those born outside the UK compared to those born in the UK and the former are more likely to have extrapulmonary TB (EPTB) (51.7% vs 30.8% respectively)1. All 47 patients in our cohort were of non-Caucasian ethnicity, with 87% having migrated from TB-endemic countries. The majority of our patients were well-established migrants with a median of 9 years since entry to the UK, mirroring national overall TB figures1.  Our cohort was predominantly young and female, in keeping with prior studies where a 1:30 male to female ratio of breast TB has been estimated6. Nearly a quarter of the women in our cohort were pregnant or breastfeeding. Both are recognised risk factors for breast TB, attributed to increased breast vascularity, tissue damage and mammary duct dilatation6-7. Our low rates of HIV co-infection reflect the national TB/HIV co-infection rate of 2.8%1. 
 
Most tuberculous breast lesions were located in the upper outer quadrant, a preponderance thought to be due to retrograde lymphatic spread of the bacilli from the axillary nodes to the adjacent upper-outer breast tissue11. Fistulation was present in a quarter; an uncommon feature among differential diagnoses such as breast cancer and bacterial abscess. Only 4% had constitutional TB symptoms, therefore a low threshold for mycobacterial culture is advocated in migrants from TB endemic areas. 

The main differential diagnosis of breast TB is breast cancer and these entities can be difficult to distinguish radiologically2-12. Ultrasound may be useful in enable differentiation of solid from cystic lesions and assessment of axillary lymph nodes and mammography may demonstrate mass lesions, skin thickening and abnormal axillary nodes12.

The gold-standard for diagnosis is culture of Mycobacterium tuberculosis (MTB), however the yield from breast tissue has been reported to be low at 3.8-19.5%2-13. When mycobacterial culture was sent, MTB was cultured in 42%; comparable to the national data on the proportion of culture confirmed extra-pulmonary TB cases (47%). In our cohort nearly 25% did not have any samples sent for mycobacterial culture and were treated on the basis of clinical, radiological and histological suspicion. However, all patients had a clinical and radiological response to anti-TB treatment.  Mycobacterial PCR was not widely used in our cohort, however other studies suggest it may be useful in the diagnosis of breast TB14. Mantoux test and interferon-gamma release assay (IGRA) are frequently positive in migrants from areas where TB is endemic and may be falsely negative in immunocompromise15. 

While a hallmark histological feature of TB infection, granulomatous inflammation may be due to other infections (e.g. non-tuberculous mycobacteria, brucellosis, histoplasmosis) or non-infectious breast pathologies (e.g. sarcoidosis, idiopathic granulomatous mastitis)6. Staining for acid-fast bacilli (AFB) is insensitive; while 6% were smear positive in our cohort the national rate for extra-pulmonary TB is just 2.6%1. Staining of nipple discharge for AFB has been reported as a useful non-invasive test for breast TB, however this was not performed in our cohort despite 40% presenting with discharge2-4. 

With appropriate treatment, outcomes for breast TB are excellent with cure rates of 95-100% and very low rates of recurrence2-3,6. However, more than one in ten in our study were left with non-infectious sequelae. Delay in initiation of TB treatment is associated with poorer outcomes, scarring and fistulation and earlier recognition and treatment could avoid the tissue destruction contributing to residual breast symptoms12. Fortunately, none of our cohort required surgery, but in other case series the rate is between 37 and 75%2,4. 
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Table 1. Summary of demographic features in patients with breast tuberculosis (N = 47)
Age (years), median (IQR)	33 (28.5-39.5)
Sex, n (%)	Male	3 (6%)
	Female	44 (94%)
Place of birth, n (%)	South Asia	30 (64%)
	Africa	6 (13%)
	South East Asia	2 (4%)
	Middle East	1 (2%)
	UK	6 (13%)
Pregnant, n (% of female cases)	3 (7%)
Lactating, n (% of female cases)	8 (18%)
Previous pulmonary TB, n (%)	6 (13%)
Contact with TB case, n (%)	1 (2%)
BCG vaccinated, n (%)	24 (51%)
HIV positive*, n (%)	1 (2%)









Table 2. Summary of clinical features of patients with breast tuberculosis (N = 47)





	Upper outer quadrant	28/32 (88%)
	Unspecified lump	7/41 (17%)
Breast pain, n (%)	24 (51%)
Nipple discharge, n (%)	19 (40%)
Erythema, n (%)	13 (28%)
Nipple inversion, n (%)	4 (9%)
Fistulation, n (%)	12 (26%)
Axillary lymphadenopathy, n (%)	15 (32%)
	Associated with breast lump	13/15 (87%)
	Isolated	1 /15 (7%)
Systemic symptoms*, n (%)	2 (4%)








Table 3. Summary of microbiological, histological and radiological investigation results in patients with breast tuberculosis (N = 47)
Investigation	Total performed, n (% = n/47)	Result	Number positive / total performed	Relative frequency (%) 
Mycobacterial culture 	36 (77%)	Positive	15/36	42%
		High level Isoniazid resistance	3/36	8%
		Fully drug sensitive	34/36	94%




Cytological examination 	23 (49%)	Necrotising granulomata 	4/23	17%
		Non-necrotising granulomata	13/23	57%
		Non-specific findings*	6/23	26%
Ziehl-Neelsen (ZN) stain 	33 (70%)	Positive†	2/33	6%
		Negative	31/33	94%
Mycobacterial PCR	4 (9%)	Positive 	0/4	0%









*reactive lymphocytosis, necrosis, other inflammatory change without granulomata
†2 histological samples, 1 cytological sample
‡Skin thickening, a suspicious looking density or both








Figure 1. Time from symptom onset to presentation and treatment (days)
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